Boule Diagnostics AB (BDABF) Stock Statistics & Valuation Metrics

Boule Diagnostics AB has a market cap or net worth of $14.58M. The enterprise value is $351.77.

Boule Diagnostics AB has 38,833,103 shares outstanding. The number of shares has decreased by -2.65% in one year.

Boule Diagnostics AB’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is -0.73%.

The current PE Ratio of Boule Diagnostics AB is ―. Boule Diagnostics AB’s PEG ratio is 0.50.

In the last 12 months, Boule Diagnostics AB had revenue of 489.70M and earned -3.80M in profits. Earnings per share was -0.10.

In the last 12 months, operating cash flow was 22.10M and capital expenditures -4.70M, giving a free cash flow of 17.40M billion.

Boule Diagnostics AB pays an annual dividend of ―, resulting in a dividend yield of ―

Boule Diagnostics AB upcoming earnings date is Oct 23, 2026, TBA (Confirmed).

Boule Diagnostics AB as a current ratio of 1.09, with Debt / Equity ratio of 129.96%

In the past 12 months, Boule Diagnostics AB has paid 9.70M in taxes.

Boule Diagnostics AB EV to EBITDA ratio is 16.90, with an EV/FCF ratio of -94.52.

Boule Diagnostics AB has $19.60M in cash and marketable securities with $227.30M in debt, giving a net cash position of -$207.70M billion.

Gross margin is 42.97%, with operating margin of 0.92%, and net profit margin of -0.78%.

The average price target for Boule Diagnostics AB is ―, which is 11.43% higher than the current price. The consensus rating is ―